The Intellectual Property and Science business of Thomson Reuters has released its annual synopsis of pharmaceutical industry trends in its 2014 Pharmaceutical R&D Factbook, compiled by CMR International, a Thomson Reuters business and world leader in global pharmaceutical R&D performance metrics. The report found a number of positive trends across the biopharmaceutical landscape - including an all-time high in pharmaceutical sales and an increase in New Molecular Entities (NMEs) and in drugs successfully completing late stage clinical trials - that contradict industry perceptions of a decline in R&D productivity.
The CMR Factbook—a publication of pharmaceutical facts containing 11 chapters of essential data on R&D pipeline volume, success rates, cycle times, regional comparisons, therapeutic areas, generics and other areas—provides valuable strategic insight to pharmaceutical industry leaders.
Information published in the CMR Factbook was compiled by the Thomson Reuters Life Sciences Professional Services team. It is based on proprietary, primary sources, competitive intelligence, and public sources covering key trends in the pharmaceutical space. For more than 15 years, CMR International has worked with the leading global pharmaceutical companies to assess R&D productivity and provide insights into industry trends to strengthen planning and effectiveness of R&D.
CMR International has published the pharmaceutical R&D Factbook, an annual report for the pharmaceutical R&D sector providing a reliable source of key reference metrics, since 2003.
